At a glance
ClinicalIndex Comparison RecordPhase 3Active· 624 enrolled
Drug / intervention
ARV-471 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ARV-471 (PF-07850327) VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE (VERITAC-2)
In Brief
A Phase 3 clinical trial evaluating ARV-471 and Fulvestrant for Advanced Breast Cancer. Active but no longer recruiting, targeting 624 participants across 312 sites in 31 countries.
Detailed Summary
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer
CountriesArgentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czechia, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Poland, Puerto Rico, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, United States
CollaboratorsArvinas Estrogen Receptor, Inc.
Timeline
Phase 3Active
202320242025202620272028
First PostedDec 2022
Enrollment StartMar 2023
Primary CompletionJan 2025
TodayJul 2026
Study CompletionMay 2028
First PostedDec 16, 2022
Enrollment StartMar 3, 2023
Primary CompletionJan 31, 2025
Study CompletionMay 15, 2028
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 3.5 years ago
Interventions
ARV-471drug
orally, once daily on a 28-day continuous dosing schedule
Fulvestrantdrug
intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle starting from C2D1 (28-day cycle)